ASX Share rice
Mon 17 May 2021 - 05:24:am (Sydney)

CGB Share Price

CANN GLOBAL LIMITEDCGBPharmaceuticals, Biotechnology & Life Sciences

CGB Company Information

Name:

Cann Global Limited

Sector:

Healthcare

Industry:

Drug Manufacturers-Specialty & Generic

Address:

133 Castlereagh Street Sydney NSW Australia 2000

Phone:

61 2 8379 1832

Exec. Chairperson & Exec. Director of Bus. Devel.:

Ms. Pnina Feldman

CEO, MD & Exec. Director:

Mr. Sholom Dovber Feldman

Chief Operating Officer:

Ms. Marion Lesaffre

Director of Sales & Marketing:

Mr. Franc Zvonar

Company Sec.:

Mr. Alexander James Neuling BSc, FCA (ICAEW), ACIS

Company Overview:

Cann Global Limited operates in medicinal cannabis and hemp food industries in Australia and internationally. The company operates through Hemp and Medical Cannabis Products, and Mining Exploration and Evaluation segments. It grows and cultivates hemp and medical cannabis products; and provides plant-based food and skin care products. The company also engages in the exploration and development of bauxite. In addition, it holds interests in the South Johnstone Project located in Queensland; and the New England Bauxite Project located in the New South Wales. The company was formerly known as Queensland Bauxite Limited and changed its name to Cann Global Limited in January 2019. Cann Global Limited was incorporated in 2007 and is based in Sydney, Australia.

CGB Share Price Information

Shares Issued:

5.71B

Market Capitalisation:

$34.25M

Revenue (TTM):

$1.99M

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.004

Profit Margin:

-2.3304

Operating Margin (TTM):

$-2.51

Return On Assets (TTM):

$-0.17

Return On Equity (TTM):

$-0.31

Quarterly Revenue Growth (YOY):

0.293

Gross Profit(TTM):

$469.86K

Diluted Earnings Per Share (TTM):

$-0.001

CGB CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-244,593

Change To Liabilities:

$356.08K

Total Cashflow From Investing Activities:

$-244,593

Net Borrowings:

$477.26K

Net Income:

$-8,012,138

Total Cash From Operating Activities:

$-4,776,262

Depreciation:

$68.56K

Change To Inventory:

$-198,057

Change To Account Receivables:

$-156,098

Sale Purchase Of Stock:

$6.62M

Capital Expenditures:

$229.84K

CGB Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-8,050,810

Net Income:

$-8,012,140

Gross Profit:

$617.87K

Operating Income:

$-6,042,230

Other Operating Expenses:

$186.06K

Interest Expense:

$392.03K

Total Revenue:

$1.93M

Cost Of Revenue:

$1.31M

CGB Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$4.50M

Total Liabilities:

$6.73M

Total Stockholder Equity:

$9.82M

Other Current Liabilities:

$360.69K

Total Assets:

$16.55M

Common Stock:

$84.16M

Retained Earnings:

$-37,870,544

Good Will:

$4.32M

Cash:

$7.42M

Total Current Liabilities:

$6.73M

Short-Term Debt:

$4.29M

Property - Plant & Equipment:

$3.08M

Net Tangible Assets:

$5.32M

Long-Term Investments:

$200K

Total Current Assets:

$8.77M

Net Receivables:

$709.63K

Short-Term Investments:

$7.78M

Inventory:

$489.48K

Accounts Payable:

$1.96M

Short-Term Investments:

$7.78

Non Current Liabilities Total:

$61.23K

CGB Share Price History

CGB News

09 Mar, 2021
Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the Australian Patent Office ("IP Australia") has granted Australian Patent No. AU 2018210690 to Canntab, related to its proprietary cannabidiol formulations with a priority date of January 23, 2017. The term of the patent expires on January 22, 2038.
11 Feb, 2021
It is a pleasure to report that the Cann Global Limited ( ASX:CGB ) is up 83% in the last quarter. But that doesn't...
05 Oct, 2020
Sholom Feldman has been the CEO of Cann Global Limited (ASX:CGB) since 2007, and this article will examine the...